Brought to you by:
First-in-human patients continue to benefit from VenoValve at average of three years post-surgery, new data show
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently presented at the VEITHsymposium 2022 (Nov. 15–19) in New York City. Principal investigator Jorge Hernando Ulloa, MD,…